Sie sind auf Seite 1von 9

Conference Program Book – Addendum

SATURDAY, OCTOBER 14, 2017


WS 01 - IASLC Supporting the Implementation of Quality Assured Global CT Screening Workshop (By Invitation
Only)

Update to presentation:
WS 01.30.02 China - National Cancer Center of China & Cancer Hospital, Chinese Academy of Medical Sciences - CT
Screening Trial
Ning Wu, National Cancer Center of China & Cancer Hospital, Chinese Academy of Medical Sciences, China

SUNDAY, OCTOBER 15, 2017


JCSE 01 – Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Cancer: Ongoing Research
from East and West

Posters Not Present:

JCSE 01.16 - Altered Expression of Programmed Death-1 Receptor (PD-1) and Its Ligand PD-L1, PD-L2 after Neo-
Adjuvant Chemotherapy in Lung Cancer
Wenyu Sun, The First Hospital of Jinlin University, CN

JCSE 01.19 – EGFR Mutation Correlates with Uninflamed Phenotype and Weak Immunogenicity, Causing Impaired
Response to PD-1 Blockade in NSCLC
Zhong-Yi Dong, Guangdong Lung Cancer Institute, Guangdong General Hospital, China

JCSE 01.22 - Is Preoperative EGFR-TKI Comparable with Chemotherapy for Stage II-IIIA Lung Adenocarcinoma?
Chao Lyu, Peking University Cancer Hospital, China

WS 04 - Minimally Invasive Diagnosis and Staging of Lung Cancer – Interventional Pulmonology Hands-On Workshop
(Ticketed Session)
Yuji Matsumoto, National Cancer Center, Japan replaced Takehiro Izumo, National Cancer Center, Japan as speaker for
MS 04.04

1|P a g e
MONDAY, OCTOBER 16, 2017
MS 02 - Ethnic Differences: Biology or Myth
Changes to the order of the presentations

Chair(s): Jeong-Seon Ryu, Korea & Ronald Natale, USA


11:00: Chemotherapy: Efficacy and Toxicity Difference According to Ethnicity - Martin Edelman, USA
11:15: Molecular Epidemiology - Tomoya Kawaguchi, Japan
11:30: Lung Cancer Genomics - Ramaswamy Govindan, USA
11:45: Targeted Agents and Immunotherapy: Efficacy and Toxicity Difference According to Ethnicity - Luis Paz-Ares,
Spain
12:00: Is Ethnicity a Prognostic Factor in Lung Cancer - Viola Zhu, USA
12:15: Q&A

MS 03 – Best Practice for Small-Sized Early Stage Lung Cancer: Standard Surgery, Limited Resection, SBRT
Masami Sato, Kagoshima University, Japan replaced Ricardo Beyruti, Brazil as chair

MA 04 – Advocacy: Listen to the Patients


Miss Danielle Hicks no longer speaking on MA 04.03

MA 05 – Immuno-Oncology: Novel Biomarker Candidates


Chair(s) - Paul Mitchell, Australia & Yoichi Nakanishi, Japan

MS 09 - Global Perspectives in Eliminating the Major Cause of Lung Cancer


Prof. Patsy Yates, QLD University of Technology, School of Nursing, Australia to replace Assoc. Prof. Stella Bialous,
UCSF School of Nursing, USA as speaker for MS 09.07

Dr. Yumiko Mochizuki presentation title changed to Holding the Tobacco Industry Accountable in the Era of Novel
Tobacco Products

OA 02 - Mesothelioma: Challenges For New Treatment


Corinne Faivre-Finn, The University of Manchester and The Christie NHS Foundation Trust, UK to replace Neil Bayman,
The Christie NHS Foundation Trust, UK for OA 02.03

OA 06 - Global Tobacco Control and Epidemiology I


Yanyan Lou, Mayo Clinic, US to replace Bhagirathbhai Dholaria, Mayo Clinic, US for OA 06.07

OA 07 - Biomarker for Lung Cancer

Update to presentation:
OA 07.03a - Impact of Tumor Mutation Burden on the Efficacy of Nivolumab or Nivolumab + Ipilimumab in Small Cell
Lung Cancer: An Exploratory Analysis of CheckMate 032
Naiyer Rizvi, Columbia University, US

2|P a g e
MTE 10 - Bridging the Gap between Genomics and Clinics (Sign Up Required)
Prof. Christian Rolfo, Antwerp University Hospital, Belgium to replace Dr. Federico Cappuzzo, Department of Oncology-
Hematology, AUSL Romagna, Italy as speaker for MTE 10.01

TUESDAY OCTOBER 17, 2017


MA 12 - Circumventing EGFR Resistance
Chair(s): Wan Ling Tan, Singapore & Nobuyuki Yamamoto, Japan

MS 12 - Sustainable Care System in Each Region


Dr. Glenwood Goss no longer speaking on MS 12.01

WEDNESDAY OCTOBER 18, 2017


ES 09 - Recent Progress in the Management of Small Cell Lung Cancer
Se-Hoon Lee no longer speaking

Updated session details:


Chair(s): David Ettinger, USA & Kenneth O'Byrne, Australia

14:30: Genomics and Translational Research - Charles Rudin, USA


14:50: Cytotoxic Chemotherapy - Yoichi Nakanishi, Japan
15:10: Immunotherapy - Caicun Zhou, China
15:30: Management of Paraneoplastic Syndromes in SCLC - Lucio Crino, Italy
15:50: NCI’s Small Cell Lung Cancer Consortium: New Answers to Old Questions - Peter Ujhazy, USA
16:10: Q&A

OA 12 - Emerging Genomic Targets


Yasir Elamin, MD Anderson Cancer Center, USA replaced John Heymach, The University of Texas MD Anderson Cancer
Center, USA as a speaker for OA 12.01

OA 18 - Lung Cancer Pathology and Genetics


Sai-Hong Ignatius Ou, University of California, Irvine School of Medicine, USA replaced Siraj Ali, Foundation Medicine,
USA as speaker for OA 18.03

MA 19 - Mesothelioma: Bench to Bedside


Thomas John, Olivia Newton-John Cancer Research Institute, Australia replaced Walter Weder, University Hospital
Zurich, Switzerland as discussant for MA 19.11

3|P a g e
MS 20 – Value-based Management for Special Populations
Dr. Hee Kyung Ahn, Gachon University Gil Medical Center, Korea replaced Byoung-Chul Cho, Yonsei Cancer Center,
Korea as the speaker for MS 20.04

MS 22 - The Cost of Lung Cancer


Danielle Hicks no longer speaking

Updated session details:


Chair(s): Ronan Kelly, USA & Tomotaka Sobue, Japan
11:00: The Economic Burden of Lung Cancer - Natasha Leighl, Canada
11:25: Health Disparities and the Costs of Tobacco Related Diseases - Peter Boyle, France
11:50: The Economic World of Tobacco Free Investments - Bronwyn King, Australia
12:15: Q&A

MS 23 - Management of N2 NSCLC: What “Operable” Means?


Dr. Marc de Perrot replaced Dr. David Jablons as chair

MS 24 - Management of GGO-Containing Nodule


Dr. Harvey Pass no longer chairing
Dr. Paul De Leyn to cover Dr. David Harpole’s presentation
Prof. Egbert Smit to cover Prof. Pieter E. Postmus’ presentation

MS 27 - Engaging Patients in Research: Best Practices


Steven Young, Addario Lung Cancer Medical Institute, USA replaced David LeDuc, Addario Lung Cancer Foundation, USA
as speaker for MS 27.03

Posters
MONDAY, OCTOBER 16, 2017

P1.01-052: Patient-Reported Outcomes (PROs) in OAK: A Phase III Study of Atezolizumab vs Docetaxel in Non-
Small-Cell Lung Cancer (NSCLC)
Marcus Ballinger, Genentech Inc., US (change in presenting author)

P1.02-039: Preventive and Therapeutic Action of Id1 Inhibition in KRAS-Mutant (KM) Lung Adenocarcinoma (LAC)
Tumors in a Xenograft Murine Model
Marta Roman Moreno, Clinica Universidad de Navarra, ES

P1.02-071a Targeting Human Single Stranded DNA Binding Protein (hSSB) 1, a Novel Prognostic Factor, in Non-
Small Cell Lung Cancer
Kenneth O’Byrne, Princess Alexandra Hospital and Queensland University of Technology, AU

4|P a g e
P1.02-071b SASH1 Is a Prognostic Indicator and Future Target in NSCLC
Kenneth O’Byrne, Princess Alexandra Hospital and Queensland University of Technology, AU

P1.03-022: A Phase 1B Study of TRC105 in Combination with Paclitaxel/Carboplatin and Bevacizumab in Patients
with Stage 4 Non-Squamous Cell Lung Cancer
Brian Simpson, Tracon Pharmaceuticals, US (change in presenting author)

P1.04-012: A Phase 1b Dose-Escalation Study of TRC105 in Combination with Nivolumab in Patients with
Metastatic Non-Small Cell Lung Cancer
Brian Simpson, Tracon Pharmaceuticals, US (change in presenting author)

P1.05-022b: Identifying Novel Markers of Early Stage Lung Cancer Using a CRISPR/Cas9 Mouse Model
Paola Marignani, Dalhousie University Tupper Medical Building 9F1, CA

P1.07-044b: Pretreatment Neutrophil/Lymphocyte Ratio and the Efficacy of Nivolumab Treatment in Non–Small-
Cell Lung Cancer
Hiroshi Kobayashi, Toho University School of Medicine, JP

P1.07-044c: Neurological Complications Following Treatment with Anti-PD1 Immune Checkpoint Inhibitors
Kenneth O’Byrne, Princess Alexandra Hospital, AU

P1.07-044d: Positive Conversion of the PD-L1 Expression after Treatments with Chemotherapy and Nivolumab
Naoki Haratake, Graduate School of Medical Sciences, Kyushu University, JP

P1.13-011a: Stratification Based on PET/CT Findings for Malignant Grade of Radiologically Pure Solid Small-Sized
(≪ 2cm) Lung Cancer
Norifumi Tsubokawa, Hiroshima City Asa Citizens Hospital, JP

P1.13-011b: Nodal Status Based on the Anatomical Location or the Number of Lymph Nodes Metastasis
Kyohei Masai, Keio University, School of Medicine, JP

P1.13-011c: A Study on the Prognosis of Hilar and Interpulmonary Lymph Nodes Patients with Pathologic T1N1M0
and T2N1M0 Disease in NSCLC
Jun Suzuki, Yamagata University Faculty of Medicine, JP

P1.13-011d Risk of Pleural Recurrence After Percutaneous Transthoracic Needle Biopsy in Stage I Non-Small Cell
Lung Cancer: A Large Center Experience
Su Yeon Ahn, Seoul National University Hospital, KR

P1.14-018a Stereotactic Ablative Radiotherapy for Ultra-Central Lung Tumors: Optimize Tumor Control or
Minimize Toxicity?
Alexander Louie, London Regional Cancer Program, CA

Posters Not Present:

P1.02-039: Main Bronchus Location Is a Predictor for Metastasis and Prognosis in Lung Adenocarcinoma: A Large
North American Cohort Analysis
Lin Yang, National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences, CN

5|P a g e
P1.10-001: Hope for People Living with Metastatic Lung Cancer
Aditya Manna, Narikeldaha Prayas, IN

P1.12-004 Therapeutic Rigid Bronchoscopy for the Locally Advanced Non-Small Cell Lung Cancer
Hisashi Tsukada, Brigham and Women's Hospital, US

TUESDAY, OCTOBER 17, 2017

P2.01-075b: Analysis of the Safety and Usefulness of Nab-Paclitaxel Therapy in Patients with Non-Small Cell
Carcinoma
Ikeya Eriko, Saiseikai Yokohamashi Tobu Hospital, JP

P2.01-075c FGFR1 as an Intrinsic Resistance Mechanism in Erlotinib Treated EGFR Mutated NSCLC
Kristine Raaby Jakobsen, Aarhus University Hospital, DK

P2.01-075d Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab: The Italian Expanded Access
Program Experience
Hector Josè Soto Parra, A.O.U. Policlinico Vittorio Emanuele, IT

P2.01-075e Neutrophil to Lymphocyte Ratio Predicts Survival in Advanced NSCLC Patients Treated with Second-
Line PD-1 Immune Checkpoint Inhibitors
Marta Batus, Rush University Medical Center, US

P2.01-075c: FGFR1 as an Intrinsic Resistance Mechanism in Erlotinib Treated EGFR Mutated NSCLC
Kristine Raaby, Aarhus University Hospital, DK

P2.02-073a Does the PD-L1 Status and TIL Intensity Change in NSCLC and Syncronous Brain Metastases?
Buge Oz, Istanbul Univercity Cerrahpasa Medical Faculty,TR

P2.09-002 Prevalence and Survival of Malignant Pleural Mesothelioma Patients Treated in a Single Brazilian Cancer
Center
Vladmir Cordeiro De Lima, BR (change in presenting author)

P2.12-006a: CT Findings Reduce the Risk of EBUS-TBNA


Kenta Kambara, Toyama University Hospital, JP

P2.13-026b: A Novel Ultra Low Cost CT Image Quality Measurement Device


Ricardo Avila, Accumetra, LLC, US

P2.14-020b: Prognostic Factors in Unresectable Stage III NSCLC Treated with Concurrent Chemoradiotherapy
Kenneth O’Byrne, Princess Alexandra Hospital and Queensland University of Technology, AU

6|P a g e
WEDNESDAY, OCTOBER 18, 2017

P3.01-043 Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the
Lung
Shirish Gadgeel, Karmanos Cancer Institute/Wayne State University (change in presenting author)

P3.01-088b: Is Efficacy Result in Phase 2 Trial Replicated in Phase 3 Trial in Advanced NSCLC: A Meta-Analysis
Ryota Shibaki, Minami Wakayama Medical Center, Japan

P3.01-088c: Exosomal Amphiregulin Induce Osteoclastogenesis Through Osteoclast Differentiation Mediated by


EGFR Pathway
Christian Rolfo, Antwerp University Hospital & Antwerp University, Belgium

P3.01-088d: TTFields Combined with PD-1 Inhibitors or Docetaxel for 2nd Line Treatment of Non-Small-Cell Lung
Cancer (NSCLC): Phase 3 LUNAR Study
Uri Weinberg, Novocure, US

P3.01-088e: TTFields Delivery to the Brain: An Overview of Computational Studies and Implications When Treating
Brain Metastases
Uri Weinberg, Novocure, US

P3.01-088f: Droplet Digital PCR-Based EGFR Mutation Detection with an Internal Quality Control Index to
Determine the Quality of DNA
Sung Su Kim, Seoul National University, KR

P3.01-088g: Variation in Treatment Recommendations for NSCLC Patients by Multidisciplinary Tumor Board
Meetings Across the Netherlands
Margriet Kwint, Netherlands Cancer Institute, NL

P3.01-088h Resistance Mechanisms Causing First-line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor
Treatment Failure
Chong-Kin Liam, University of Malaya, MY

P3.01-088i Phase Ib Trial of Xentuzumab and Abemaciclib in Advanced or Metastatic Solid Tumors, including
Advanced NSCLC
Daniel Portsmouth, Boehringer Ingelheim RCV, AT

P3.01-088j The Transitions of Prognostic Understanding and Its Associated Factors in Japanese Patients with
Advanced Lung Cancer and Their Caregivers
Daisuke Arai, Saiseikai Utsunomiya Hospital, JP

P3.02-097f: Rare Actionable Mutations in a Lung Adenocarcinoma Cohort in Brazil


Carlos Gil Ferreira, Koc Neotorax Oncologia D'or, BR

P3.02-097g LRIG1 and LMO7 Are Interacting Proteins with Clinical Significance in NSCLC
Samuel Kvarnbrink, Radiation Sciences, SE

7|P a g e
P3.02-097h Mutational Analysis of Multiple Lung Cancers: Discrimination between Primary and Metastatic Lung
Cancers by Genomic Profile
Taichiro Goto, Yamanashi Central Hospital, JP

P3.02-097i Neutrophil to Lymphocyte Ratio may be a Prognostic Factor in Advanced Stage Lung Cancer Patients
Bülent Karagöz, Okan University Hospital, TR

P3.04-013b: TTFields and Radiosurgery for 1-10 Brain Metastases from NSCLC: The Phase 3 METIS Study
Uri Weinberg, Novocure, US

P3.05-012a: Inference of Gene Expressions Associated with Recurrence of Non-Small Cell Lung Cancer
Seo Ree Kim, The Catholic University of Korea, Korea

P3.07-010 T Helper 17 Cell Related Cytokines as a Prognostic Factor in Lung Cancer Patients
Bülent Karagöz, Okan University Hospital, TR

P3.07-013c: Computational Simulations for Investigating Electric Field Distributions When Delivering Tumor
Treating Fields (TTFields) to the Lungs
Uri Weinberg, Novocure, US

P3.07-013d: Tumor Treating Fields Induce Immunogenic Cell Death and Enhance Antitumor Effects of Anti-PD1 in
NSCLC In-Vivo Models
Uri Weinberg, Novocure, US

P3.08-006a Predictive Value of Geriatric Assessment and Screening Tools in Elderly Patients with Stage III NSCLC
for Concurrent Chemoradiation
Earnest Nadal, Catalan Institute of Oncology, ES

P3.09-010a: Late Response to Pembrolizumab in Advanced Biphasic Pleural Mesothelioma


Timothy Clay, St John of God Hospital, AU

P3.09-010b: Predicting Response to First Line Chemotherapy in Pleural Mesothelioma: A Random Forest Tree
Model (Meso-CLICaP)
Oscar Arrieta, Instituto Nacional de Cancerologia, MX

P3.12-004b: All Cause In-Hospital Mortality on Diagnostic Bronchoscopy in Lung Cancer Patients: Data from the
Japanese DPC Database
Yoshihisa Hiraishi, University of Tokyo Hospital, JP

P3.16-022: Surgery for Non-Small-Cell Lung Cancer with Malignant Minor Pleural Effusion Detected on
Thoracotomy
Toshiya Yokota, Mitsui Memorial Hospital, JP

P3.16-025 Tumor Doubling Time Is the Most Important Predictor of Survival and Pathological Diagnosis in
Metachronous Lung Cancer
Keisuke Asakura, National Cancer Center Hospital, JP

8|P a g e
Poster Not Present:

P3.07-010 Immunotherapies Evaluation in an Ex-Vivo Culture Model of NSCLC


Jair Bar, Thoracic Cancer Unit, Sheba Cancer Center and Institute of Oncology, Tel HaShomer, IL

P3.16-022: Segmentectomy for Lung Adenocarcinoma: The Impact of EGFR Mutation Status on Recurrence
KwanyongHyun, Seoul National University Hospital, KR

P3.16-025 Development and Validation of a Survival Nomogram in Elderly Patients with Resected Non-Small-Cell
Lung Cancer
Xizhao Sui, Peking University People's Hospital, CN

9|P a g e